Substance use & poisoningDual NOP/μ-opioid receptor partial agonist reduces meth self-administrationGiven the absence of approved pharmacotherapies for methamphetamine (meth) use disorder (MUD), compounds that co-activate NOP and μ-opioid receptors are being explored as a potential therapeutic strategy to modulate drug-seeking behavior and reduce relapse risk. Researchers from Florida Atlantic University presented preclinical efficacy data on PPL-138, a bifunctional NOP/μ-opioid receptor partial agonist exhibiting preferential activity at NOP receptors over μ-opioid receptors.